Breathlessness in cancer patients

Published:April 23, 2008DOI:


      Breathlessness (or dyspnoea) is a common symptom experienced by cancer patients. It may be iatrogenic and is often caused or aggravated by co-morbidity. Recent studies have elucidated the neural and chemical controls of breathing which may be involved in the production of dyspnoea. A rational approach involves making a diagnosis of aetiology and treating reversible causes wherever possible. The main approaches for palliation of dyspnoea include anti-cancer treatments; drugs; oxygen and airflow; non-medical approaches. Further research is needed to clarify the best pharmacological regimens and the place of more invasive interventions.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dudgeon D.J.
        • Kristjanson L.
        • Sloan J.A.
        • Lertzman M.
        • Clement K.
        Dyspnea in Cancer Patients: Prevalence and Associated Factors.
        J Pain Symptom Manage. 2001; 21: 02-95
        • Hauser C.A.
        • Stockler M.R.
        • Tattersall M.H.N.
        Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review.
        Support Care Cancer. 2006; 14: 999-1011
        • Ahmedzai S.H.
        Cough in cancer patients.
        Pulm Pharmacol Therap. 2004; 17: 415-423
        • Gillette M.A.
        • Schwartzstein R.M.
        Mechanisms of dyspnoea.
        in: Ahmedzai S.H. Muers M. Supportive Care in Respiratory Disease. OUP, Oxford2005: 93-122 (Chap 6)
        • von Leupold A.
        • Dahme B.
        Cortical substrates for the perception of dyspnoea.
        Chest. 2005; 128: 345-354
        • Rock L.L.K.
        • Schwartzstein R.M.
        Mechanisms of dyspnea in chronic lung disease.
        Curr Opin Support Palliat Care. 2007; 1: 102-108
        • Piepoli M.F.
        • Kaczmarek A.
        • Francis D.P.
        • Davies C.L.
        • et al.
        Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure.
        Circulation. 2006; 114: 126-134
        • Parsons L.M.
        • Egan G.
        • Liotti M.
        • Brannan S.
        • et al.
        Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air.
        PNAS. 2001; 4: 2041-2046
        • Manzke T.
        • Guenther U.
        • Ponimaskin E.G.
        • Haller M.
        • et al.
        5HT4A receptors avert opiods-induced breathing depression without loss of analgesia.
        Science. 2003; : 226-229
        • Muers M.F.
        Opioids for dyspnoea.
        Thorax. 2002; 57: 922-923
        • Yorke J.
        Dyspnoea and pain: an interesting analogy.
        J Clin Nurs. 2008; : 841-842
        • Reid M.B.
        • Lannergren J.
        • Westerblad K.
        Respiratory and limb muscle weakness induced by tumour necrosis factor – alpha.
        Am J Respir Crit Care Med. 2002; 166: 479-484
        • Tanaka K.
        • Akewchi T.
        • Okuyama T.
        • Nishiwaki Y.
        • Uchitomi Y.
        Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale.
        Brit J Cancer. 2000; 82: 800-805
        • Vora V.A.
        • Ahmedzai S.H.
        Pulse oximetry in supportive and palliative care.
        Support Care Cancer. 2004; 12: 758-761
      1. Hoskin P, Ahmedzai SH. Assessment and management of respiratory symptoms of malignant disease. In: Ahmedzai SH, Muers M, editors. Supportive Care in Respiratory Disease. Oxford: OUP; 2005. p. 463–86. Chap 30.

      2. Kvale PA, Selecky PA, Prakash UBS. Palliative care in lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007:132; 368S-403S.

        • Saffran L.
        • Ost D.E.
        • Fein A.M.
        • Schiff M.J.
        Outpatient pleurodesis of malignant pleural effusions using a small-bore Pigtail catheter.
        Chest. 2000; 118: 417-421
        • Neragi-Miandoab S.
        Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology.
        Support Care Cancer. 2008;
        • Navigante A.H.
        • Cerchietti L.C.A.
        • Castro M.A.
        • Lutteral M.A.
        • Cabalar M.E.
        Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnoea perception in patients with advanced cancer.
        J Pain Symptom Manage. 2006; 31: 38-47
        • Jennings A.-L.
        • Davies A.N.
        • Higgins J.P.T.
        • Gibbs J.S.R.
        • Broadley K.E.
        A systematic review of the use of opioids in the management of dyspnoea.
        Thorax. 2002; 57: 939-944
        • Abernethy A.P.
        • Currow D.C.
        • Frith P.
        • Fazekas B.S.
        Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea.
        BMJ. 2003; 327: 523-528
        • Poole P.J.
        • Vele A.G.
        • Black P.N.
        The efect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 1998; 157: 1877-1880
        • Clemens K.E.
        • Klaschik E.
        Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative care patients.
        J Pain Symptom Manage. 2007; 33: 473-481
        • Dahan A.
        • Yassen A.
        • Romberg R.
        • Sarton E.
        • et al.
        Buprenorphine induces ceiling in respiratory depression but not in analgesia.
        Brit J Anaesthesia. 2006; 96: 627-632
        • Nishino T.
        • Ide T.
        • Sudo T.
        • Sato J.
        Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnoea.
        Am J Respir Crit Care Med. 2000; 161: 1963-1967
        • Moosavi S.H.
        • Binks P.A.
        • Lansing R.W.
        • Topulos G.P.
        • Banzett R.B.
        • Schwartzstein R.M.
        Effect of inhaled furosemide on air hunger induced in healthy humans.
        Respiratory Physiology & Neurobiology. 2007; 156: 1-8
        • Kohara H.
        • Ueoka H.
        • Aoe K.
        • Maeda T.
        • et al.
        Effect of nebulized furosemide in terminally ill cancer patients with dyspnoea.
        J Pain Symptom Manage. 2003; 26: 962-967
        • Booth S.
        • Anderson H.
        • Swannick M.
        • Wade R.
        • et al.
        The use of oxygen in the palliation of breathlessness.
        Resp Med. 2004; 98: 66-77
        • Ahmedzai S.H.
        • Laude E.
        • Robertson A.
        • Troy G.
        • Vora V.
        A double-blind, randomised, controlled Phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion.
        Brit J Cancer. 2004; 90: 366-371
        • Schwartzstein R.M.
        • Lahive K.
        • Pope A.
        • Weinberger S.E.
        • Weiss J.W.
        Cold facial stimulation reduces breathlessness induced in normal subjects.
        Am Rev Respir Dis. 1987; 136: 58-61
        • MacLeod R.
        Psychosocial therapies.
        in: Ahmedzai S.H. Muers M. Supportive Care in Respiratory Disease. OUP, Oxford2005: 229-238 (Chap 13)
        • Morita T.
        • Tsunoda A.H.
        • Inoue S.
        • Chihara S.
        Contributing factors to physical symptoms in terminally-ill cancer patients.
        J Pain Symptom Manage. 1999; 18: 338-346
        • Morita T.
        • Chinone Y.
        • Ikenaga M.
        • Miyoshi M.
        • et al.
        Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan.
        J Pain Symptom Manage. 2005; 30: 308-319
        • Bennett M.
        • Lucas V.
        • Brennan M.
        • Hughes A.
        • et al.
        Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care.
        Palliat Med. 2002; 16: 369-374